Biomarker-Driven Therapy for NSCLC: Experts Discuss Current and Future Trends

Download All
Gain expert guidance on optimal use of biomarkers to guide treatment decisions for advanced NSCLC with this educational program featuring an on-demand webcast and downloadable slidesets from a live CCO webinar along with a podcast of the experts answering questions from the audience.
Jamie E. Chaft, MD
Stephen V. Liu, MD
Nathan Pennell, MD, PhD

Downloadable Slidesets

Download these slides from a live CCO Webinar for an overview of the current status of biomarkers guiding optimal use of frontline targeted therapy in the treatment of advanced NSCLC.

Nathan Pennell, MD, PhD Released: April 14, 2021

Download these slides from a live CCO Webinar for an overview of emerging biomarkers and targeted therapies showing promise in the treatment of advanced NSCLC.

Stephen V. Liu, MD Released: April 14, 2021

Download these slides from a live CCO Webinar for an overview of precision medicine in advanced NSCLC along with the current status of biomarkers guiding optimal use of immunotherapy for the treatment of this disease.

Jamie E. Chaft, MD Released: April 14, 2021

Download this short summary slideset of key takeaways from a live CCO Webinar featuring an overview of the current status of biomarkers guiding optimal use of targeted therapy and immunotherapy in the treatment of advanced NSCLC.

Jamie E. Chaft, MD Stephen V. Liu, MD Nathan Pennell, MD, PhD Released: April 21, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Lilly
Regeneron Pharmaceuticals, Inc & Sanofi Genzyme

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue